BR9912109B1 - compostos derivados de quinolina, composições farmacêuticas, processo para a manufatura de um composto, e, uso de um composto. - Google Patents

compostos derivados de quinolina, composições farmacêuticas, processo para a manufatura de um composto, e, uso de um composto.

Info

Publication number: BR9912109B1
Authority: BR; Brazil
Prior art keywords: compound; manufacture; pharmaceutical compositions; quinoline derivatives; quinoline
Prior art date: 1998-07-15

Application number

BRPI9912109-3A

Other languages

English (en)

Other versions

BR9912109A (pt

Inventor

Anders Bjoerk

Stig Joensson

Tomas Fex

Gunnar Hedlund

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-15

Filing date

1999-07-14

Publication date

2012-08-21

1999-07-14 Application filed filed Critical

2001-05-02 Publication of BR9912109A publication Critical patent/BR9912109A/pt

2012-08-21 Publication of BR9912109B1 publication Critical patent/BR9912109B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Quinoline Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI9912109-3A 1998-07-15 1999-07-14 compostos derivados de quinolina, composições farmacêuticas, processo para a manufatura de um composto, e, uso de um composto. BR9912109B1 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9802549A SE9802549D0 (sv)	1998-07-15	1998-07-15	Quinoline derivatives
PCT/SE1999/001270 WO2000003991A1 (en)	1998-07-15	1999-07-14	Quinoline derivatives

Publications (2)

Publication Number	Publication Date
BR9912109A BR9912109A (pt)	2001-05-02
BR9912109B1 true BR9912109B1 (pt)	2012-08-21

Family

ID=20412093

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI9912109-3A BR9912109B1 (pt)	1998-07-15	1999-07-14	compostos derivados de quinolina, composições farmacêuticas, processo para a manufatura de um composto, e, uso de um composto.

Country Status (32)

Country	Link
EP (1)	EP1095021B1 (pt)
JP (1)	JP4045070B2 (pt)
KR (1)	KR100516382B1 (pt)
CN (1)	CN1157378C (pt)
AP (1)	AP1366A (pt)
AT (1)	ATE250036T1 (pt)
AU (1)	AU751103B2 (pt)
BR (1)	BR9912109B1 (pt)
CA (1)	CA2336968C (pt)
CZ (1)	CZ300229B6 (pt)
DE (1)	DE69911415T2 (pt)
DK (1)	DK1095021T3 (pt)
EE (1)	EE04673B1 (pt)
ES (1)	ES2205854T3 (pt)
HR (1)	HRP20010039B1 (pt)
HU (1)	HU229427B1 (pt)
ID (1)	ID27423A (pt)
IL (2)	IL140346A0 (pt)
IS (1)	IS2208B (pt)
ME (1)	ME00374B (pt)
NO (1)	NO317601B1 (pt)
NZ (1)	NZ508923A (pt)
OA (1)	OA11906A (pt)
PL (1)	PL199783B1 (pt)
PT (1)	PT1095021E (pt)
RS (1)	RS50128B (pt)
RU (1)	RU2213733C2 (pt)
SE (1)	SE9802549D0 (pt)
TR (1)	TR200100087T2 (pt)
UA (1)	UA64791C2 (pt)
WO (1)	WO2000003991A1 (pt)
ZA (1)	ZA200007593B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100390148C (zh) *	1999-10-25	2008-05-28	活跃生物技术有限公司	用于治疗恶性肿瘤的药物
SE0002320D0 (sv) *	1999-10-25	2000-06-21	Active Biotech Ab	Malignant tumors
CA2487891A1 (en) *	2002-06-05	2003-12-18	Institute Of Medicinal Molecular Design, Inc.	Inhibitors against the activation of ap-1 and nfat
KR101118807B1 (ko)	2002-06-06	2012-04-12	가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼	Ｏ-치환 히드록시아릴 유도체
TWI280127B (en) *	2002-06-11	2007-05-01	Inst Med Molecular Design Inc	Remedies for neurodegenerative diseases
SE0400235D0 (sv)	2004-02-06	2004-02-06	Active Biotech Ab	New composition containing quinoline compounds
US8314124B2 (en)	2004-02-06	2012-11-20	Active Biotech Ab	Crystalline salts of quinoline compounds and methods for preparing them
MY134672A (en) *	2004-05-20	2007-12-31	Japan Tobacco Inc	Stable crystal of 4-oxoquinoline compound
SE0401578D0 (sv) *	2004-06-18	2004-06-18	Active Biotech Ab	Novel compounds
PL1937642T3 (pl)	2005-10-19	2015-02-27	Teva Pharma	Kryształy lakwinimodu sodu i proces ich wytwarzania
KR20140091778A (ko)	2006-06-12	2014-07-22	테바 파마슈티컬 인더스트리즈 리미티드	안정한 라퀴니모드 제제
WO2008113006A1 (en) *	2007-03-14	2008-09-18	Xenon Pharmaceuticals Inc.	Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
PL2234485T3 (pl)	2007-12-20	2014-06-30	Teva Pharma	Stabilne preparaty lakwinimodu
ES2633658T3 (es)	2008-09-03	2017-09-22	Teva Pharmaceutical Industries Ltd.	Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria
DE102010048788A1 (de)	2009-02-13	2011-05-19	Amw Gmbh	Transdermales System mit Immunmodulator
DE102009008851A1 (de)	2009-02-13	2010-08-19	Amw Gmbh	Transdermales System mit Immunmodulator
BR112012002124A2 (pt)	2009-07-30	2015-09-15	Teva Pharma	tratamento da doença de crohn com laquinimode.
HRP20160997T1 (hr)	2009-08-10	2016-10-07	Teva Pharmaceutical Industries Ltd.	Liječenje poremećaja povezanih s bdnf primjenom lakvinimoda
DE102010026879A1 (de)	2010-02-11	2011-08-11	AMW GmbH, 83627	Transdermales System mit Immunmodulator
SG10201501535UA (en)	2010-03-03	2015-04-29	Teva Pharma	Treatment of lupus nephritis using laquinimod
DK2542079T3 (da)	2010-03-03	2014-08-25	Teva Pharma	Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
WO2012006538A1 (en)	2010-07-09	2012-01-12	Teva Pharmaceutical Industries Ltd.	Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
KR101983979B1 (ko) *	2010-08-27	2019-05-30	그뤼넨탈 게엠베하	Ｋｃｎｑ２／３ 조절제로서의 치환된 ２-옥소- 및 ２-티옥소-디하이드로퀴놀린-３-카복스아미드
CN103153959A (zh)	2010-10-14	2013-06-12	伊姆纳尔公司	作为AhR活化剂的1，2-二氢-4-羟基-2-氧代-喹啉-3-甲酰苯胺类
EP2537517A1 (en)	2011-06-22	2012-12-26	Active Biotech AB	Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
WO2013055907A1 (en)	2011-10-12	2013-04-18	Teva Pharmaceutical Industries Ltd.	Treatment of multiple sclerosis with combination of laquinimod and fingolimod
SG11201404214QA (en)	2012-02-03	2014-08-28	Teva Pharma	USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
KR20140138725A (ko)	2012-02-16	2014-12-04	테바 파마슈티컬 인더스트리즈 리미티드	N-에틸-n-페닐-1,2-디하이드로-4,5-디-하이드록시-1-메틸-2-옥소-3-퀴놀린카복사미드, 그의 제조 및 용도
TW201350467A (zh)	2012-05-08	2013-12-16	Teva Pharma	Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh)	2012-06-05	2014-01-01	Teva Pharma	使用拉喹莫德治療眼發炎疾病
TW201410244A (zh)	2012-08-13	2014-03-16	Teva Pharma	用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
HK1215210A1 (zh)	2012-11-07	2016-08-19	Teva Pharmaceutical Industries Ltd.	拉喹莫德胺盐
JP5868839B2 (ja)	2012-12-27	2016-02-24	三菱重工業株式会社	チャー払出管
NZ630427A (en)	2013-03-14	2017-06-30	Teva Pharma	Crystals of laquinimod sodium and improved process for the manufacture thereof
HK1231413A1 (zh)	2014-04-29	2017-12-22	Teva Pharmaceutical Industries Ltd.	用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
CN108358842A (zh) *	2014-08-28	2018-08-03	杭州普晒医药科技有限公司	他喹莫德的晶型及其制备方法、其药物组合物和用途
US9956212B2 (en)	2014-09-23	2018-05-01	Active Biotech Ab	Quinoline carboxamides for use in the treatment of multiple myeloma
WO2016078921A1 (en)	2014-11-19	2016-05-26	Active Biotech Ab	Quinoline carboxamides for use in the treatment of leukemia
EP3067062A1 (en)	2015-03-13	2016-09-14	Ipsen Pharma S.A.S.	Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
WO2018105943A1 (ko) *	2016-12-07	2018-06-14	순천향대학교 산학협력단	폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물
CN115209881A (zh)	2020-03-03	2022-10-18	活跃生物技术有限公司	用于组合疗法的他喹莫德或其药学上可接受的盐
KR20230043916A (ko)	2020-07-23	2023-03-31	에라스무스 유니버시티 메디컬 센터 로테르담	골수증식성 신생물의 새로운 치료학적 표적으로서 s100 단백질
US20240091215A1 (en)	2021-01-18	2024-03-21	Active Biotech Ab	Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
PL4346773T3 (pl)	2021-05-25	2025-11-03	Active Biotech Ab	Duża liczba cząstek taskwinimodu i ich zastosowanie
KR20240029029A (ko)	2021-07-02	2024-03-05	액티브 바이오테크 에이비	타스퀴니모드를 함유한 약학적 제품 및 이러한 제품의 순도 평가 방법
AR126963A1 (es) *	2021-09-13	2023-12-06	Lilly Co Eli	Agonistas de ahr
TWI838849B (zh) *	2021-09-13	2024-04-11	美商美國禮來大藥廠	Ahr促效劑

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE52670B1 (en) *	1981-03-03	1988-01-20	Leo Ab	Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) *	1991-04-22	1991-06-05	Fujisawa Pharmaceutical Co	Quinoline derivatives
DE4120646A1 (de) *	1991-06-22	1992-12-24	Bayer Ag	7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
SE469368B (sv) *	1991-10-09	1993-06-28	Kabi Pharmacia Ab	Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms)
SE9201076L (sv) *	1992-04-06	1993-10-07	Shimon Slavin	Användningen av gamla läkemedel för behandling av diabetes
JPH07224040A (ja) *	1994-02-07	1995-08-22	Fujisawa Pharmaceut Co Ltd	キノリン誘導体
GB9404378D0 (en) *	1994-03-07	1994-04-20	Fujisawa Pharmaceutical Co	Quinoline derivatives
SE9400809D0 (sv) *	1994-03-10	1994-03-10	Pharmacia Ab	New use of quinoline-3-carboxamide compounds
SE9400810D0 (sv) *	1994-03-10	1994-03-10	Pharmacia Ab	New use of Quinoline-3-carboxamide compounds
GB2290786A (en) *	1994-06-30	1996-01-10	Fujisawa Pharmaceutical Co	Quinoline derivatives

1998
- 1998-07-15 SE SE9802549A patent/SE9802549D0/xx unknown
1999
- 1999-07-14 WO PCT/SE1999/001270 patent/WO2000003991A1/en not_active Ceased
- 1999-07-14 HR HR20010039A patent/HRP20010039B1/xx not_active IP Right Cessation
- 1999-07-14 CZ CZ20010094A patent/CZ300229B6/cs not_active IP Right Cessation
- 1999-07-14 KR KR10-2000-7014618A patent/KR100516382B1/ko not_active Expired - Fee Related
- 1999-07-14 BR BRPI9912109-3A patent/BR9912109B1/pt not_active IP Right Cessation
- 1999-07-14 PL PL345388A patent/PL199783B1/pl unknown
- 1999-07-14 DK DK99933452T patent/DK1095021T3/da active
- 1999-07-14 AP APAP/P/2001/002041A patent/AP1366A/en active
- 1999-07-14 JP JP2000560098A patent/JP4045070B2/ja not_active Expired - Fee Related
- 1999-07-14 RU RU2001104342/04A patent/RU2213733C2/ru not_active IP Right Cessation
- 1999-07-14 EP EP99933452A patent/EP1095021B1/en not_active Expired - Lifetime
- 1999-07-14 UA UA2000127299A patent/UA64791C2/uk unknown
- 1999-07-14 HU HU0103224A patent/HU229427B1/hu not_active IP Right Cessation
- 1999-07-14 IL IL14034699A patent/IL140346A0/xx active IP Right Grant
- 1999-07-14 ES ES99933452T patent/ES2205854T3/es not_active Expired - Lifetime
- 1999-07-14 ID IDW20010331A patent/ID27423A/id unknown
- 1999-07-14 AU AU49504/99A patent/AU751103B2/en not_active Ceased
- 1999-07-14 AT AT99933452T patent/ATE250036T1/de active
- 1999-07-14 CN CNB998085987A patent/CN1157378C/zh not_active Expired - Fee Related
- 1999-07-14 CA CA002336968A patent/CA2336968C/en not_active Expired - Fee Related
- 1999-07-14 DE DE69911415T patent/DE69911415T2/de not_active Expired - Lifetime
- 1999-07-14 OA OA00100011A patent/OA11906A/en unknown
- 1999-07-14 RS YUP-15/01A patent/RS50128B/sr unknown
- 1999-07-14 NZ NZ508923A patent/NZ508923A/xx not_active IP Right Cessation
- 1999-07-14 TR TR2001/00087T patent/TR200100087T2/xx unknown
- 1999-07-14 EE EEP200100010A patent/EE04673B1/xx unknown
- 1999-07-14 ME MEP-2008-574A patent/ME00374B/me unknown
- 1999-07-14 PT PT99933452T patent/PT1095021E/pt unknown
2000
- 2000-12-14 IL IL140346A patent/IL140346A/en not_active IP Right Cessation
- 2000-12-18 ZA ZA200007593A patent/ZA200007593B/xx unknown
- 2000-12-18 IS IS5775A patent/IS2208B/is unknown
2001
- 2001-01-12 NO NO20010211A patent/NO317601B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CZ300229B6 (cs)	2009-03-25
NZ508923A (en)	2002-09-27
IL140346A (en)	2006-07-05
UA64791C2 (en)	2004-03-15
HRP20010039A2 (en)	2001-12-31
IL140346A0 (en)	2002-02-10
SE9802549D0 (sv)	1998-07-15
IS2208B (is)	2007-02-15
JP2002520395A (ja)	2002-07-09
RS50128B (sr)	2009-03-25
NO20010211L (no)	2001-03-15
EP1095021A1 (en)	2001-05-02
CN1309641A (zh)	2001-08-22
HRP20010039B1 (en)	2009-04-30
NO317601B1 (no)	2004-11-22
CN1157378C (zh)	2004-07-14
EP1095021B1 (en)	2003-09-17
AU4950499A (en)	2000-02-07
YU1501A (sh)	2003-10-31
PL345388A1 (en)	2001-12-17
CA2336968C (en)	2005-08-30
BR9912109A (pt)	2001-05-02
NO20010211D0 (no)	2001-01-12
MEP57408A (en)	2011-05-10
IS5775A (is)	2000-12-18
CA2336968A1 (en)	2000-01-27
KR20010053115A (ko)	2001-06-25
AP1366A (en)	2005-01-26
WO2000003991A1 (en)	2000-01-27
CZ200194A3 (en)	2001-05-16
ID27423A (id)	2001-04-05
HU229427B1 (en)	2013-12-30
HK1035715A1 (en)	2001-12-07
ZA200007593B (en)	2001-07-09
AU751103B2 (en)	2002-08-08
ME00374B (me)	2011-05-10
DK1095021T3 (da)	2003-11-24
PL199783B1 (pl)	2008-10-31
OA11906A (en)	2006-04-10
TR200100087T2 (tr)	2001-06-21
ES2205854T3 (es)	2004-05-01
DE69911415T2 (de)	2004-07-08
RU2213733C2 (ru)	2003-10-10
HUP0103224A2 (hu)	2002-01-28
EE200100010A (et)	2002-06-17
JP4045070B2 (ja)	2008-02-13
ATE250036T1 (de)	2003-10-15
HUP0103224A3 (en)	2002-11-28
PT1095021E (pt)	2003-12-31
KR100516382B1 (ko)	2005-09-26
AP2001002041A0 (en)	2001-03-31
DE69911415D1 (de)	2003-10-23
EE04673B1 (et)	2006-08-15

Publication	Publication Date	Title
BR9912109B1 (pt)	2012-08-21	compostos derivados de quinolina, composições farmacêuticas, processo para a manufatura de um composto, e, uso de um composto.
BR9909925B1 (pt)	2010-09-21	derivados de quinolina, composições farmacêuticas, e, processo para a fabricação de derivados de quinolina.
BR9912104B1 (pt)	2010-07-13	compostos derivados de quinolina, composições farmacêuticas, e, processo para a manufatura de um composto.
BR9810802B1 (pt)	2010-10-19	composto, composição farmacêutica, e, processo para a preparação de um composto.
BR9909995B1 (pt)	2010-07-13	composto, processo para a preparação de um composto, formulação farmacêutica, e, uso de um composto.
BR9808422B1 (pt)	2010-08-24	composto, composiÇço farmacÊutica, uso de um composto, e, processo para a preparaÇço de um composto.
BR9807814B1 (pt)	2009-01-13	composto de pirazina, composiÇço farmacÊutica, uso de um composto, e, processo para a preparaÇço de um composto.
BR9810829B1 (pt)	2009-08-11	composto heterocìclico, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica.
BR0009083B1 (pt)	2011-11-01	derivado de amida compreendendo um núcleo de quinazolinona, processo para a preparação de um derivado de amida, composição farmacêutica, e, uso de um derivado de amida.
BR0008301B1 (pt)	2013-01-22	processo para a fabricaÇço de compostos, e, compostos.
BR9906934B1 (pt)	2010-08-24	composto, catalisador, processo para preparar uma poliolefina, e, uso de um catalisador.
BR9911182B1 (pt)	2010-09-08	compostos derivados de biarila com propriedades agonistas de adrenorreceptores beta-3, uso de um composto, composição farmacêutica, e, processo para a preparação de um composto.
BR9806870B1 (pt)	2009-05-05	composto amidino, formulação farmacêutica, uso de um composto, e, processo papa preparar o mesmo.
BR9801606B1 (pt)	2010-07-27	composto, processo para sua preparação, substáncia farmacêutica, uso do composto e processo para a produção de uma substáncia farmacêutica.
BR9711311B1 (pt)	2009-01-13	derivado de 1,2,3,4-tetrahidroquinolina, composiÇço farmaceutica, uso de um derivado de 1,2,3,4-tetrahidroquinolina, e, processo para a preparaÇço de compostos.
BR9907230B1 (pt)	2008-11-18	processo para a preparaÇço de um macrâmero.
EE04721B1 (et)	2006-10-16	Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine
BR9803720B1 (pt)	2009-05-05	composto de pigmento de quinoxalina-monoazo-acetarilida, processo para a preparação e uso do mesmo.
BR9906373B1 (pt)	2010-11-16	compostos pirimidinona, composições farmacêuticas contendo os compostos e processos para a preparação dos mesmos.
BR9908472B1 (pt)	2013-11-05	Processo para a preparação de um composto aminometil-pirrolidina-3-ona protegido, e, composto
BRPI0012475B8 (pt)	2021-07-06	composto derivado de titânio, seu processo de preparação e utilização, bem como composição para uso oral compreendendo o mesmo.
BR9917475B1 (pt)	2013-07-23	processo para a manufatura de compostos, e, modificação do processo.
EE200000657A (et)	2002-04-15	Asoolid, nende valmistamismeetod, kasutamine ravimina ja farmatseutiline kompositsioon
BRPI9914571B1 (pt)	2011-10-18	composto, processo para sua preparação, uso do mesmo, bem como composição farmacêutica.
BR9807682B1 (pt)	2009-01-13	composto, uso do mesmo, composiÇço farmacÊutica, e, processos para preparar um composto.

Legal Events

Date	Code	Title	Description
2009-02-17	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2009-02-17	B15K	Others concerning applications: alteration of classification	Free format text: ALTERADA DA INT.CL: C07D 215/56, A61K 31/4741, A61K 31/4704, A61K 31/47, A61P 37/02, A61P 37/00, A61P 9/10, A61P 11/06, A61P 17/06, A61P 19/02, A61P 25/28 Ipc: C07D 215/56 (2009.01), A61K 31/4741 (2009.01), A61
2009-09-01	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2010-03-23	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2011-08-30	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2012-06-05	B09X	Republication of the decision to grant [chapter 9.1.3 patent gazette]
2012-08-21	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/08/2012, OBSERVADAS AS CONDICOES LEGAIS.
2019-05-07	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 20A ANUIDADE.
2019-08-27	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2522 DE 07-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.